Teitur Trophics raises EUR 28 million in Series A financing co-led by Sunstone Life Science Ventures and Sound Bioventures
Biotech company Teitur Trophics completes a EUR 28 million Series A financing to advance the development and treatment for neurodegenerative diseases.
The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. Mazanti Transactions advised Sunstone Life Science Ventures, Sound Bioventures, and Industrifonden in connection with the investment.
Teitur Trophics is dedicated to developing new treatments for patients suffering from neurodegenerative diseases. It develops first-in-class circular peptides for treating neurodegenerative disorders where there are no treatments currently available including Parkinson’s Disease, Frontotemporal Dementia and Huntington’s Disease.
The proceeds will enable Teitur to progress its lead drug candidate, TT-P34, from candidate selection into clinical development.
Read more here.